RESEARCH TRIANGLE PARK, N.C., Oct. 10, 2016 /PRNewswire/ -- Envisia Therapeutics today announced that it has been selected to present during the Anterior Segment Company Showcase at the 2016 Ophthalmology Innovation Summit (OIS) being held at 8:30am CDT on October 13, 2016 at the Planet Hollywood Hotel in Chicago, Illinois. Commonly referred to as OIS@AAO, the summit is held each year in conjunction with the American Academy of Ophthalmology (AAO) Annual Meeting to facilitate meaningful interactions and business partnerships between physicians, entrepreneurs, investors and industry executives who are driving ophthalmic innovation.
"We are honored that Envisia has been selected to take part in the OIS@AAO showcase for companies with differentiated anterior segment therapies," said Ben Yerxa, PhD, President of Envisia. "Our ENV515 travoprost extended-release glaucoma program is generating promising long-term data and we value the opportunity to highlight our progress in the program at OIS."
Dr. Yerxa will present interim clinical data for the ENV515 travoprost XR glaucoma program and an overview of how Envisia is using the power of the proprietary PRINT® (Particle Replication In Non-Wetting Templates) technology platform to advance its second program, ENV1105 dexamethasone XR, into clinical development.
ENV515 is a fully biodegradable PRINT-particle formulation of a marketed prostaglandin analog that has the potential to lower intraocular pressure (IOP) for more than 6 months from a single dose. ENV515 was designed to address the issue of poor patient compliance that exists today with daily eye drops and limit the progression of glaucoma that sometimes leads to vision loss. Envisia is also leveraging the Company's unique platform technology to develop products for other leading ocular diseases, including age-related macular degeneration (AMD) and diabetic macular edema (DME).
ABOUT ENVISIA THERAPEUTICS™
Envisia Therapeutics is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® technology platform to develop therapies for a variety of ocular conditions, beginning with ENV515 for glaucoma. ENV515 is a novel, extended-release formulation of a marketed prostaglandin analogue with the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is actively exploring the use of the company's unique technology to develop products for other important ocular diseases including age -related macular degeneration (AMD) and diabetic macular edema (DME). Envisia is located in Research Triangle Park, North Carolina. For more information, please go to www.envisiatherapeutics.com.
SOURCE Envisia Therapeutics